Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News MSD vaccine adoption ‘demonstrates value’

MSD vaccine adoption ‘demonstrates value’

17th July 2007

Merck, Sharp and Dohme (MSD) has announced the adoption of Rotateq (rotavirus vaccine, live, oral, pentavalent) and Gardasil [quadrivalent human papillomavirus (types six, 11, 16, 18) Recombinant Vaccine] by an immunisation programme, reporting that this adoption shows the value of these products.

The vaccines have been adopted by the Vaccines for Children (VFC) scheme of the Centres for Disease Control and Prevention, with projects for each of the 50 US states and a further five city plans for Chicago, Philadelphia, New York City, San Antonio and Washington DC.

Founded in 1994, VFC provides vaccines for uninsured or underinsured children who do not have private healthcare insurance.

Mark Feinberg, vice-president of policy, public health and medical affairs, Merck Vaccines, said: “This milestone is an important step in Merck’s ongoing commitment to make our vaccines available to all children who need them, regardless of income.”

He added that the adoption of these compounds by all immunisation schemes nationwide shows the value of these vaccines.

Furthermore, the company has announced the submission for prequalification status for these vaccines to the World Health Organisations to reflect the company’s dedication to broadening access to these products in developing countries.

In February 2007, MSD announced an update to its prescribing information for Rotateq, in order to improve transparency and confidence in the safety of the drug following a number of reported cases of intussusception.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.